<i>FABP3</i> methylation as a novel biomarker for the differentiation and classification of benign and malignant thyroid nodules.

ABSTRACT:

Introduction

Differentiation between benign and malignant thyroid nodules has been a challenge in clinical practice. We aim to explore a novel biomarker to determine the malignancy of thyroid nodules.

Methods

In the discovery study, 32 tissue samples from benign thyroid nodule (BTN) and thyroid cancer (TC) patients were analyzed by Methylation 850K array and RNA-Sequencing. TC associated FABP3 methylation was further verified by mass spectrometry in two independent studies (221 BTN vs. 222 TC in Validation I and 191 BTN vs. 256 TC in Validation II). Logistic regression analysis and non-parametric tests were used for the analysis between groups.

Results

Altered and inversely correlated methylation and expression in the FABP3 gene in TC was found in the di

SUBMITTER: Huang H 

PROVIDER: S-EPMC12462056 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature